Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients

Annals of Oncology

Volumn 19, Issue 8, 2008, Pages 1458-1464

  Jacot, W ^a   Colinet, B ^a,c   Bertrand, D ^a   Lacombe, S ^b   Bozonnat, M C ^b   Daures J P ^b   Pujol, J L ^a,b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UNIV MONTPELLIER   (France)

^c Hopital St Joseph   (Belgium)

Author keywords

Comorbidities; Non small cell lung cancer; Prognosis; Quality of life

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE;

ADJUVANT THERAPY; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER STAGING; CHARLSON COMORBIDITY INDEX; DAILY LIFE ACTIVITY; FEMALE; HUMAN; HYPONATREMIA; LUNG CANCER SYMPTOMS SCALE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SCORING SYSTEM; SIMPLIFIED COMORBIDITY SCORE; SURVIVAL TIME; UNIVARIATE ANALYSIS;

EID: 48749114956     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn064     Document Type: Article

References (30)

1. Komaki R, Pajak TF, Byhardt RW et al. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: Comparison with CALGB 8433. Lung Cancer 1993; 10: 189-197.
2. Mountain CF. Revisions in the international System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
3. Charloux A, Hedelin G, Dietemann A et al. Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer 1997; 17: 123-134.
4. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 1047-1057.
5. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
6. Colinet B, Jacot W, Bertrand D et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005; 93: 1098-1105.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
8. Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 1996; 23: 31-40.
9. Hollen PJ, Gralla, RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993; 29A (Suppl 1): S51-S58.
10. Brambilla E, Travis WD, Colby TV et al. The World Health Organization. Eur Respir J 2001; 18: 1059-1068.
11. Zubrod C, Schneiderman M, Frei EJ. Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960; 11: 7-33.
12. Sobin L, Hermanek P, Hutter RVP. TNM Classification of Malignant Tumours 4th edition. UICC: Geneva 1987.
13. Vansteenkiste JF, Stroobants SS. PET scan in lung cancer: Current recommendations and innovation. J Thorac Oncol 2006; 1: 71-73.
14. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004. CD002140.
15. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: Prospective study in 621 patents. Lung Cancer 2001; 31: 221-231.
16. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958: 53: 457-481.
17. Cox D. Regression models and life tables. J R Stat Soc 1972; 34B: 187-220.
18. Andersen PK. Survival analysis 1982-1991: The second decade of the proportional hazards regression model. Stat Med 1991; 10: 1931-1941.
19. Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: Advantages, problems, and suggested solutions. Cancer Treat Rep 1985; 69: 1071-1077.
20. Asmis TR, Ding K, Seymour L et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: A review of national cancer institute of Canada clinical trials group trials. J Clin Oncol 2008; 26: 54-59.
21. Takigawa N, Segawa Y, Okahara M et al. Prognostic factors for patients with advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996; 15: 67-77.
22. Aoe K, Hiraki A, Maeda T et al. Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer. Intern Med 2005; 44: 800-804.
23. Jacot W, Quantin X, Boher JM et al. Brain metastases at the time of presentation of non-small cell lung cancer: A multi-centric AERIO analysis of prognostic factors. Br J Cancer 2001; 84: 903-909.
24. van Zandwijk N, Jassem E, Bonfrer JM et al. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol 1992; 19: 37-43.
25. Lopez-Encuentra A. Comorbidity in operable lung cancer: A multicenter descriptive study on 2992 patents. Lung Cancer 2002; 35: 263-269.
26. Feinstein AR, Wells CK. A clinical-severity staging system for patients with lung cancer. Medicine (Baltimore) 1990; 69: 1-33.
27. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991; 67: 3131-3135.
28. Dancey J, Zee B, Osoba D et al. Quality of life scores: An independent prognostic variable in a general population of cancer patents receiving chemotherapy. The National Cancer institute of Canada Clinical Trials Group. Qual Life Res 1997; 6: 151-158.
29. Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002; 55: 285-295.
30. Hollen PJ, Gralla RJ, Kris MG et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994; 73: 2087-2098.